key: cord-0888850-7fua6mvd
authors: Griffiths, Paul D.
title: Protection offered by SARS coronavirus 2 vaccines against disease and infection
date: 2021-10-05
journal: Rev Med Virol
DOI: 10.1002/rmv.2303
sha: 3ab2b61e1273c258a347fa1ab09fcfc1095cfc7f
doc_id: 888850
cord_uid: 7fua6mvd

nan

The second is to develop a non-replicating vaccine to be given intranasally, or perhaps orally, to stimulate mucosal IgA antibodies.

It is clear that the objective of controlling the spread of SARS-CoV-2 will be a long haul endeavour that will be aided by learning from past examples of successful vaccinology. The rapid development of the currently licensed vaccines has been a major achievement in terms of preventing disease and death, but the answer to the distinct problem of transmission of virus is not necessarily more of the same.

Immunologic correlates of protection induced by vaccination

Poliomyelitis control in Israel, the West Bank and Gaza Strip: changing strategies with the goal of eradication in an endemic area

Covid-19: time for a paradigm change

The reproductive number of the Delta variant of SARS-CoV-2 is far higher compared to the ancestral SARS-CoV-2 virus

Quantifying the risk of SARS-CoV-2 reinfection over time

Potency of BNT162b2 and mRNA-1273 vaccine-induced neutralizing antibodies against severe acute respiratory syndrome-CoV-2 variants of concern: a systematic review of in vitro studies

Detection of SARS-CoV-2-specific IgA in the human milk of COVID-19 vaccinated lactating health care workers

The levels of SARS-CoV-2 specific antibodies in human milk following vaccination

A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults

Profile Books